MX9307946A - Derivados de amina secundaria ciclica, un procedimiento para su preparacion, composiciones farmaceuticas que los contienen y su uso. - Google Patents
Derivados de amina secundaria ciclica, un procedimiento para su preparacion, composiciones farmaceuticas que los contienen y su uso.Info
- Publication number
- MX9307946A MX9307946A MX9307946A MX9307946A MX9307946A MX 9307946 A MX9307946 A MX 9307946A MX 9307946 A MX9307946 A MX 9307946A MX 9307946 A MX9307946 A MX 9307946A MX 9307946 A MX9307946 A MX 9307946A
- Authority
- MX
- Mexico
- Prior art keywords
- derivatives
- procedure
- contain
- preparation
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
El uso de un compuesto de la fórmula (I) (ver fórmula) en donde: w es -(CH2)4, (CH2)5,-(CH2)2 O(CH2)2 o-(CH2)2S((CH2)2; n es 0 a 6; m es 0 a 3; A es una unión, -CHCH-, CC_, oxígeno, azufre o NR1; R1 es hidrógeno, alquilo de 1 a 8 átomos de carbono o fenilalquilo de 1 a 4 átomos de carbono; y Ar es arilo o heteroarilo, cada uno de los cuales puede estar sustituido opcionalmente; o una sal farmacéuticamente aceptable del mismo, como un agente terapéutico. También se describen ciertos aspectos novedosos de la fórmula (I) y los procedimientos para prepararlos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929226111A GB9226111D0 (en) | 1992-12-15 | 1992-12-15 | Madicaments |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9307946A true MX9307946A (es) | 1994-08-31 |
Family
ID=10726633
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9307946A MX9307946A (es) | 1992-12-15 | 1993-12-14 | Derivados de amina secundaria ciclica, un procedimiento para su preparacion, composiciones farmaceuticas que los contienen y su uso. |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0674514A1 (es) |
JP (1) | JPH08504419A (es) |
CN (1) | CN1091636A (es) |
AU (1) | AU5698394A (es) |
GB (1) | GB9226111D0 (es) |
MX (1) | MX9307946A (es) |
WO (1) | WO1994013291A1 (es) |
ZA (1) | ZA939317B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9314973D0 (en) * | 1993-07-20 | 1993-09-01 | Smithkline Beecham Plc | Medicaments |
GB9411052D0 (en) * | 1994-06-02 | 1994-07-20 | Smithkline Beecham Plc | Medicaments |
GB9411045D0 (en) * | 1994-06-02 | 1994-07-20 | Smithkline Beecham Plc | Compounds and use |
WO1996002494A1 (en) * | 1994-07-14 | 1996-02-01 | Smithkline Beecham Plc | Benzocycloalkylamine derivatives as calcium channel antagonists |
US5794887A (en) | 1995-11-17 | 1998-08-18 | Komerath; Narayanan M. | Stagnation point vortex controller |
EP0790235A1 (en) * | 1996-02-15 | 1997-08-20 | Sankyo Company Limited | Diaryl alkane derivatives containing an alicyclic group, their preparation and their therapeutic and prophylactic uses |
US6110937A (en) * | 1997-04-03 | 2000-08-29 | Syntex Usa, Inc. | Phenoxymethyl piperidine derivatives for the treatment of neuropathic pain |
CA2232147A1 (en) * | 1997-04-03 | 1998-10-03 | F. Hoffmann-La Roche Ag | Phenoxymethyl piperidine derivatives |
WO1999043658A1 (en) | 1998-02-27 | 1999-09-02 | Warner-Lambert Company | Heterocyclic substituted aniline calcium channel blockers |
US6166052A (en) | 1998-03-11 | 2000-12-26 | Warner-Lambert Company | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers |
AU2398001A (en) * | 1999-12-21 | 2001-07-03 | Mitsubishi Pharma Corporation | Remedies and/or preventives for nervous system disorders |
EP1318988A2 (en) | 2000-09-11 | 2003-06-18 | Sepracor, Inc. | Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission) |
US7294637B2 (en) | 2000-09-11 | 2007-11-13 | Sepracor, Inc. | Method of treating addiction or dependence using a ligand for a monamine receptor or transporter |
BRPI0408136A (pt) | 2003-03-07 | 2006-03-01 | Astellas Pharma Inc | derivados heterocìclicos contendo nitrogênio tendo estirila 2,6-dissubstituìda |
DE602005021871D1 (de) | 2004-02-27 | 2010-07-29 | Lilly Co Eli | 4-aminopiperidinderivate als inhibitoren der monoamin-aufnahme |
US7417040B2 (en) | 2004-03-01 | 2008-08-26 | Bristol-Myers Squibb Company | Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
KR101328306B1 (ko) | 2005-09-21 | 2013-11-11 | 디코드 제네틱스 이에이치에프 | 염증 치료를 위한 lta4h의 바이아릴 치환된헤테로사이클 억제제 |
AU2006327245A1 (en) * | 2005-12-21 | 2007-06-28 | Decode Genetics Ehf | Biaryl substituted nitrogen containing heterocycle inhibitors of LTA4H for treating inflammation |
CN107846898B (zh) | 2015-05-01 | 2023-07-14 | 佐治亚州立大学研究基金会 | 用于管理低氧诱导因子相关病症的二苯基甲醇衍生物 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1096441A (en) * | 1964-01-15 | 1967-12-29 | Bristol Myers Co | Ethers of benzyl phenols and a process for the preparation thereof |
US3381013A (en) * | 1964-01-15 | 1968-04-30 | Bristol Myers Co | Heterocyclicamino ethers of benzylphenols |
GB1203149A (en) * | 1968-06-10 | 1970-08-26 | Ici Ltd | Piperidine derivatives |
GB1319252A (en) * | 1969-06-05 | 1973-06-06 | Ciba Geigy Ag | 1-phenyl-alkanols and process for making same |
DE2728898A1 (de) * | 1977-06-27 | 1979-01-18 | Thomae Gmbh Dr K | Neue morpholinderivate |
DE2811952A1 (de) * | 1978-03-18 | 1979-10-31 | Merck Patent Gmbh | Phenoxyalkylamine und verfahren zu ihrer herstellung |
FR2443246A1 (fr) * | 1978-12-05 | 1980-07-04 | Pharmindustrie | Nouveaux medicaments a base de derives de la phenyl-1 (piperidyl-4)-3 propanone-1 |
IE66332B1 (en) * | 1986-11-03 | 1995-12-27 | Novo Nordisk As | Piperidine compounds and their preparation and use |
DK231088D0 (da) * | 1988-04-28 | 1988-04-28 | Ferrosan As | Piperidinforbindelser, deres fremstilling og anvendelse |
US4822778A (en) * | 1988-01-19 | 1989-04-18 | Gunnar Aberg | Membrane stabilizing phenoxy-piperidine compounds and pharmaceutical compositions employing such compounds |
US5169855A (en) * | 1990-03-28 | 1992-12-08 | Du Pont Merck Pharmaceutical Company | Piperidine ether derivatives as psychotropic drugs or plant fungicides |
MX9100513A (es) * | 1990-08-06 | 1992-04-01 | Smith Kline French Lab | Compuestos |
MX9100517A (es) * | 1990-08-06 | 1992-04-01 | Smith Kline French Lab | Compuestos |
GB9113031D0 (en) * | 1991-06-17 | 1991-08-07 | Smithkline Beecham Plc | Compounds |
EP0629190A1 (en) * | 1992-01-28 | 1994-12-21 | Smithkline Beecham Plc | Compounds as calcium channel antagonists |
-
1992
- 1992-12-15 GB GB929226111A patent/GB9226111D0/en active Pending
-
1993
- 1993-12-07 WO PCT/EP1993/003473 patent/WO1994013291A1/en not_active Application Discontinuation
- 1993-12-07 JP JP6513782A patent/JPH08504419A/ja active Pending
- 1993-12-07 EP EP94902735A patent/EP0674514A1/en not_active Withdrawn
- 1993-12-07 AU AU56983/94A patent/AU5698394A/en not_active Abandoned
- 1993-12-13 ZA ZA939317A patent/ZA939317B/xx unknown
- 1993-12-14 CN CN93112828A patent/CN1091636A/zh active Pending
- 1993-12-14 MX MX9307946A patent/MX9307946A/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO1994013291A1 (en) | 1994-06-23 |
EP0674514A1 (en) | 1995-10-04 |
AU5698394A (en) | 1994-07-04 |
CN1091636A (zh) | 1994-09-07 |
GB9226111D0 (en) | 1993-02-10 |
JPH08504419A (ja) | 1996-05-14 |
ZA939317B (en) | 1995-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9307946A (es) | Derivados de amina secundaria ciclica, un procedimiento para su preparacion, composiciones farmaceuticas que los contienen y su uso. | |
AR032453A1 (es) | Derivados alquinil fenil heteroaromaticos activadores de glucoquinasa, un proceso para su preparacion, composiciones farmaceuticas, el uso de dichos derivados para la preparacion de medicamentos | |
MX9203264A (es) | Nuevos derivados de la tieno(3,2-c)piridina y composiciones farmaceuticas que los contienen. | |
MX9305379A (es) | Nuevos derivados de aminoacidos, procedimiento para su preparacion y preparado farmaceutico que los contiene. | |
DK34793A (da) | Vandoploeseligt, farmaceutisk acceptabelt salt af et monoacylderivat af rapamycin, fremgangsmaade til dets fremstilling og injicerbart, farmaceutisk praeparat indeholdende det | |
MX9203239A (es) | Derivados de 1-(dihidroxifenil)-2-amino-etanol y composiciones farmaceuticas que los contienen. | |
SE9904508D0 (sv) | New compounds | |
AR011093A1 (es) | Compuestos derivados de sulfonil urea, composicion farmaceutica que los contiene y procedimiento para su uso. | |
AR033306A1 (es) | Compuestos | |
ES2127919T3 (es) | 4-amino-piridinas, procedimiento para su preparacion, asi como medicamentos que contienen estos compuestos. | |
DE69003200T2 (de) | Arylsubstituierte Aminderivate verwendbar in der Krebstherapie. | |
ES2095942T3 (es) | Derivados de bencenoacetamida inhibidores del vih. | |
DE69015736D1 (de) | 7-Keto- und 7-Hydroxy-androsta-3,5-dien-3-carbonsäure Derivate. | |
ATE18218T1 (de) | Antifungische triazolyl-propanol-derivate. | |
FI834702A (fi) | Nya nitroalifatiska foereningar, deras framstaellningsfoerfarande och anvaendning. | |
ES2056073T3 (es) | Aril-aralquil-eteres, procedimientos para su preparacion y composicion farmaceutica que los comprende. | |
AR018632A1 (es) | Compuestos derivados de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico, su uso en la fabricacion de medicamentos, composicion farmaceutica que los contiene, proceso para su preparacion. | |
BR0113987A (pt) | Composto heteromático bicìclico, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de derivados heteroaromáticos bicìclicos ou de um sal ou solvato farmaceuticamente aceitável dos mesmos | |
MX9306394A (es) | Derivados de benzofurano, proceso para su preparacion y composicion farmaceutica que los contiene | |
ES2057802T3 (es) | Nuevos derivados de 3-amino-cromano, procedimiento de preparacion y composiciones farmaceuticas que los contienen. | |
DK661088D0 (da) | N-(23-vinblastinoyl)derivater af 1-aminomethylphosphonsyre, fremgangsmaade til deres fremstilling og farmaceutiske midelr indeholdende dem | |
AR027454A1 (es) | Derivados de beta-alanina, utiles como antagonistas de receptores, las composiciones farmaceuticas que las contienen y el uso de los mismos para lapreparacion de medicamentos | |
NO20006350L (no) | Derivater av 3-(2-okso-[1,3']bipyrrolidinyl-3-ylidenmetyl)- cephemer | |
ES2053755T3 (es) | Un procedimiento para preparar compuestos heterociclicos. | |
AR029741A1 (es) | Uso de compuestos heterociclicos n-sustituidos para la preparacion de medicamentos para la profilaxis y la terapia de la isquemia cerebral y la apoplejia |